Loading
The randomised trial of mogamulizumab outside Japan, in which confirmed responses were seen in 11 per cent of people with relapsed adult T-cell leukaemia/lymphoma against none with chemotherapy.
A randomised phase 2 study in the United States, Europe and Latin America of mogamulizumab against the investigator's choice of chemotherapy in relapsed or refractory aggressive adult T-cell leukaemia/lymphoma of the acute, lymphoma and chronic subtypes, randomised 2:1 with stratification by subtype. The primary endpoint was overall response confirmed on a later assessment at eight weeks by blinded independent review.
The evidence on mogamulizumab for the people with this disease who are treated in Europe and the Americas, mostly of Caribbean, African or Latin American origin. It shows activity, with a confirmed response rate far below the Japanese figure.
Shares CCR4, Mogamulizumab, Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares CCR4, Mogamulizumab, Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Study 0761-009: mogamulizumab against investigator's choice in relapsed adult T-cell leukaemia/lymphoma, CCR4, Mogamulizumab, Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares CCR4, Mogamulizumab, Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Adult T-cell leukaemia/lymphoma and the tag lymphoma-evidence-entities.
Shares Study 0761-009: mogamulizumab against investigator's choice in relapsed adult T-cell leukaemia/lymphoma, Adult T-cell leukaemia/lymphoma.
Shares Study 0761-009: mogamulizumab against investigator's choice in relapsed adult T-cell leukaemia/lymphoma, CCR4, Mogamulizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/